Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Classical hematology 2Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Anemia 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Radiation Injuries 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms 1

Interventions

pembrolizumab 14Specimen Handling 8Docetaxel 8olaparib 7Nivolumab 7Gemcitabine 7Trastuzumab 6Paclitaxel 6rucaparib 5Magnetic Resonance Spectroscopy 5Early Intervention, Educational 5Biopsy 5Standard of Care 4Cyclophosphamide 4Carboplatin 4tisotumab vedotin 3talazoparib 3pertuzumab 3durvalumab 3atezolizumab 3Taxes 3Surveys and Questionnaires 3Sirolimus 3Radiotherapy 3Psychiatric Rehabilitation 3Methods 3Irinotecan 3Immunoglobulin G 3Fulvestrant 3Educational Status 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Epoetin Alfa × Gynecologic × Clear all
NCT00270166 2011-05-18

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
201 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicLymphoidPlasma cellThoracic

Anemia, Breast Neoplasms, Esophageal Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡